Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22364226 | 0.81 | XDH (0.43) | XDHSLC22A12SGK1 | |
| SCHEMBL17941585 | 0.66 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL22364244 | 0.65 | XDH (0.45) | XDHLMNAHTT | |
| SCHEMBL22364270 | 0.65 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL22381453 | 0.64 | XDH (0.54) | XDHSLC22A12 | |
| SCHEMBL13411815 | 0.64 | POLB (0.33) | MEN1KMT2A | |
| SCHEMBL22381445 | 0.64 | XDH (0.50) | XDHSLC22A12 | |
| SCHEMBL22381440 | 0.63 | XDH (0.49) | XDHSLC22A12 | |
| SCHEMBL22624285 | 0.62 | CREBBP (0.33) | XDH | |
| SCHEMBL28644304 | 0.62 | KIF11 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347034-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885SGK1 3602/4885 |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885SGK1 3602/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885SGK1 3602/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885SGK1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.